Categories
Markets

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the use of the “at-the market” equity of its offering program.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out a “at the market” equity offering program under which Acasti might issue and market from time to time its common shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares had been marketed at prevailing market rates averaging US$1.0747 per share. No securities were marketed in the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March five, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and can provide the Company with more flexibility in its ongoing review process to explore and evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescribed drugs making use of OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy and safety in lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for clients with severe HTG.

Forward Looking Statements – ACST Stock

Statements of this press release which aren’t statements of historical or current truth constitute “forward looking information” within the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims include known and unknown risks, uncertainties, as well as other unknown variables that could result in the particular outcomes of Acasti to be materially different from historical success and even as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, readers are actually urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this press release. Forward-looking claims in that press release include, but are not limited to, info or statements about Acasti’s strategy, future operations and the review of its of strategic alternatives.

The forward-looking claims found in this press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor aisle of Acasti’s site at www.acastipharma.com. All forward-looking assertions in this press release exist as of the date of this particular press release.

ACST Stock – Acasti does not undertake to redesign any such forward looking statements whether as a direct result of brand new info, future events or otherwise, except as needed by law. The forward-looking assertions contained herein are also subject generally to assumptions and risks and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage

Leave a Reply

Your email address will not be published. Required fields are marked *